Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy

Annals of Hematology

Volumn 91, Issue 2, 2012, Pages 299-300

  Piccin, Andrea ^a   Grana, Chiara Maria ^b   Negri, Giovanni ^a   Pusceddu, Irene ^a   Paganelli, Giovanni ^b   Cortelazzo, Sergio ^a  

^a San Maurizio Regional Hospital   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTARABINE; DOTATATE LU 177; DOTATOC Y 90; ETOPOSIDE; IDARUBICIN; RADIOISOTOPE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ADULT; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CARCINOMA; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; DISEASE COURSE; DYSPLASIA; HUMAN; LETTER; LYMPH NODE METASTASIS; MALE; MYELODYSPLASTIC SYNDROME; NEUROENDOCRINE CARCINOMA; NEUROENDOCRINE DISEASE; PANCREAS TUMOR; PANCYTOPENIA; PRIORITY JOURNAL; SALVAGE THERAPY; TUMOR VOLUME; VATER PAPILLA TUMOR;

EID: 84943014229     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1237-9     Document Type: Letter

References (8)

1. EP Krenning JJ Teunissen R Valkema WW de Herder M de Jong DJ Kwekkeboom 2005 Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors J Endocrinol Invest 28 11 Suppl International 146 150 16625865 1:STN:280:DC%2BD283hvFSjsA%3D%3D
2. L Bodei D Ferone CM Grana M Cremonesi A Signore RA Dierckx G Paganelli 2009 Peptide receptor therapies in neuroendocrine tumors J Endocrinol Invest 32 4 360 369 19636207 1:CAS:528:DC%2BD1MXhsVeitLfM
3. L Bodei M Cremonesi M Ferrari M Pacifici CM Grana M Bartolomei SM Baio M Sansovini G Paganelli 2008 Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors Eur J Nucl Med Mol Imaging 35 10 1847 1856 18427807 10.1007/s00259-008-0778-1 1:CAS:528:DC%2BD1cXhtFCjtbzP
4. M Cremonesi M Ferrari A Di Dia F Botta C De Cicco L Bodei G Paganelli 2011 Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy Q J Nucl Med Mol Imaging 55 2 155 167 21386788 1:STN:280:DC%2BC3M3ltFChtw%3D%3D
5. DJ Kwekkeboom J Mueller-Brand G Paganelli LB Anthony S Pauwels LK Kvols TM O'dorisio R Valkema L Bodei M Chinol HR Maecke EP Krenning 2005 Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs J Nucl Med 46 Suppl 1 62S 66S 15653653 1:CAS:528: DC%2BD2MXhsVeksLs%3D (Pubitemid 47619020)
6. E Merola G Capurso D Campana F Panzuto B Monarca P Tomassetti G Delle Fave 2010 Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid Dig Liver Dis 42 6 457 458 19783489 10.1016/j.dld.2009.08.004
7. ML Sierra A Agazzi L Bodei M Pacifici D Aricò C De Cicco J Quarna M Sansovini M De Simone G Paganelli 2009 Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC Cancer Biother Radiopharm 24 6 659 665 20025545 10.1089/cbr.2009.0641 1:CAS:528:DC%2BC3cXisV2mug%3D%3D
8. Flach J, Dicker F, Schnittger S, Schindela S, Kohlmann A, Haferlach T, Kern W, Haferlach C (2011) An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling. Leukemia 25(4):713-718